Combination Therapy Shown As Effective For Higher-Risk MDS/AML Patients
A phase two study that investigated the potential of the drugs
azacitidine (AZA) and lenalidomide (LEN), demonstrated that the two
therapies in combination may be an effective frontline treatment regimen
for patients with higher-risk forms of myelodysplastic syndrome and
acute myeloid leukemia. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 7, 2014 Category: Cancer & Oncology Source Type: news
Investigational oral drug combo shows promise for newly diagnosed multiple myeloma
(Mayo Clinic) The investigational drug ixazomib taken orally in combination with lenalidomide and dexamethasone shows promise in patients with newly diagnosed multiple myeloma, according to the results of a phase 1/2 study published in the journal Lancet Oncology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 17, 2014 Category: Cancer & Oncology Source Type: news
Investigational Oral Drug Combo Shows Promise for Newly Diagnosed Multiple Myeloma in Mayo Clinic-Led Study
ROCHESTER, Minn. — The investigational drug ixazomib taken orally in combination with lenalidomide and dexamethasone shows promise in patients with newly diagnosed multiple myeloma, according to the results of a phase 1/2 study published in the journal Lancet Oncology. "Ixazomib is an investigational, oral proteasome inhibitor with promising anti-myeloma effects and low rates of peripheral [...] (Source: Mayo Clinic Rochester News)
Source: Mayo Clinic Rochester News - November 17, 2014 Category: Hospital Management Source Type: news
Rituximab + Lenalidomide Effective in Follicular Lymphoma
Response rate, progression - free survival comparable to those seen with rituximab - chemotherapy (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 11, 2014 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Journal, Source Type: news
Continuous Lenalidomide Plus Dexamethasone FIRST in MyelomaContinuous Lenalidomide Plus Dexamethasone FIRST in Myeloma
For older multiple myeloma patients ineligible for transplantation, interim results from the FIRST trial suggest that continuous lenalidomide and dexamethasone is better than the standard of care. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 5, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Phase III FIRST (MM-020/IFM 07-01) trial of REVLIMID (lenalidomide) plus dexamethasone in newly diagnosed multiple myeloma patients who are not candidates for stem cell transplant published in New England Journal of Medicine
(dna Communications) The study met the primary endpoint as a significant progression-free survival benefit was seen for patients treated with continuous REVLIMID plus dexamethasone compared with those treated with a standard of care. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 4, 2014 Category: Cancer & Oncology Source Type: news
Study Results Published Showing Advantages with Revlimid in Newly Diagnosed Myeloma
The New England Journal of Medicine published a study this week showing that Revlimid (lenalidomide) plus low-dose dexamethasone improves survival and other measures of efficacy compared to MPT (melphalan, prednisone, and thalidomide) in newly diagnosed multiple myeloma patients who are not eligible for a stem cell transplant. The study also showed that continuing use of Revlimid-dexamethasone instead of stopping after a fixed number of treatments provided further advantages in multiple measures (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - September 4, 2014 Category: Hematology Source Type: news
The IMF Says Newly Published Study Confirms Survival Advantage with Revlimid® and Further Advantages With Continuous Use in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Transplant
(Source: International Myeloma Foundation)
Source: International Myeloma Foundation - September 4, 2014 Category: Hematology Source Type: news
The International Myeloma Foundations Says Newly Published Study Confirms Survival Advantage with Revlimid® and Further Advantages With Continous Use in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Transplant
--Publication in the New England Journal of Medicine Follows Presentation Highlighted at ASH 2013--
--Supports US and European Approval of REVLIMID in New Diagnosed Multiple Myeloma-- (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - September 4, 2014 Category: Hematology Source Type: news
Phase III FIRST (MM-020/IFM 07-01) trial of REVLIMID® (lenalidomide) plus dexamethasone in newly diagnosed multiple myeloma patients who are not candidates for stem cell transplant published in New England Journal of Medicine
(dna Communications) Study met the primary endpoint as a significant progression-free survival benefit was seen for patients treated with continuous REVLIMID plus dexamethasone compared with those treated with a standard of care. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 4, 2014 Category: Cancer & Oncology Source Type: news
NHS England launches plan for a sustainable Cancer Drugs Fund
The amount pledged will give more patients access to innovative drugs not routinely available on the NHS.
Two new drugs will now also be added to the Fund: enzalutamide for prostate cancer and lenalidomide for a group of patients with myelodysplastic syndrome, a rare blood condition.
With an annual budget of £200m, now rising by 40 per cent to £280m, the Fund has delivered important benefits for more than 55,000 patients since it began in 2010. More .... (Source: NHS Networks)
Source: NHS Networks - August 29, 2014 Category: UK Health Authors: Maria Axford Source Type: news
NICE recommends Celgene’s Revlimid to treat myelodysplastic syndromes
The UK National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending Celgene's Revlimid (lenalidomide) to treat myelodysplastic syndromes (MDS). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 20, 2014 Category: Pharmaceuticals Source Type: news
New NICE position on lenalidomide
NICE has issued final draft guidance recommending lenalidomide as an option for treating myelodysplastic syndromes. (Source: Pharmacy Europe)
Source: Pharmacy Europe - August 20, 2014 Category: Drugs & Pharmacology Authors: AMcculloch Tags: *** Editor's Pick Haematology celgene Latest News lenalidomide myelodysplastic syndromes nice revlimid Source Type: news
NICE recommends lenalidomide for treating blood disorders
NICE has issued final draft guidance recommending lenalidomide, an immunomodulatory drug also known as Revlimid, as an option for treating myelodysplastic syndromes (MDS). (Source: Nursing Times Breaking News)
Source: Nursing Times Breaking News - August 20, 2014 Category: Nursing Source Type: news
UK cost agency backs Celgene bone marrow drug in change of tack
LONDON (Reuters) - Celgene's drug Revlimid should be an option on Britain's state health service for patients with serious bone marrow disorders and a specific chromosomal abnormality, the country's cost agency said on Wednesday. (Source: Reuters: Health)
Source: Reuters: Health - August 19, 2014 Category: Consumer Health News Tags: healthNews Source Type: news
